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Humans are virtually identical in their genetic makeup, yet the small differences in our DNA give rise to tremendous
phenotypic diversity across the human population. By contrast, the metagenome of the human microbiome—the
total DNA content of microbes inhabiting our bodies—is quite a bit more variable, with only a third of its constituent
genes found in a majority of healthy individuals. Understanding this variability in the “healthy microbiome” has thus
been a major challenge in microbiome research, dating back at least to the 1960s, continuing through the Human
Microbiome Project and beyond. Cataloguing the necessary and sufficient sets of microbiome features that support
health, and the normal ranges of these features in healthy populations, is an essential first step to identifying and
correcting microbial configurations that are implicated in disease. Toward this goal, several population-scale studies
have documented the ranges and diversity of both taxonomic compositions and functional potentials normally
observed in the microbiomes of healthy populations, along with possible driving factors such as geography, diet, and
lifestyle. Here, we review several definitions of a ‘healthy microbiome’ that have emerged, the current understanding of
the ranges of healthy microbial diversity, and gaps such as the characterization of molecular function and the
development of ecological therapies to be addressed in the future.Background
Humans have co-evolved with the trillions of microbes
that inhabit our bodies and that create complex, body–
habitat-specific, adaptive ecosystems that are finely
attuned to relentlessly changing host physiology. Dys-
bioses in the microbiome have been associated with nu-
merous diseases, including inflammatory bowel disease,
multiple sclerosis, diabetes (types 1 and 2), allergies,
asthma, autism, and cancer [1–5]. Like the concept of
the pathogenicity of a single microbial taxon, dysbiosis
of a microbial community can be difficult to define but
could be considered as a perturbation that departs from
an otherwise balanced ecology [1] to prolong, exacer-
bate, or induce a detrimental health effect. Thus, finding
features that broadly distinguish healthy from unhealthy
microbiomes will aid in the diagnosis of microbiome-
related diseases and could potentially provide new
means to prevent disease onset or to improve prognosis.
Many potential features common to healthy micro-
biomes have been proposed, including prevalent organ-
isms or molecular pathways [6] as well as norms of* Correspondence: chuttenh@hsph.harvard.edu
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[7, 8]. Microbiomes regularly show a large degree of
interpersonal diversity even in the absence of disease
[7, 9]. This complicates the identification of simple
microbial constituents or imbalances that either cause
disease or reflect a diseased state. An understanding
of the properties of a healthy microbiome, and the many
different microbial ecologies that are encountered in the
absence of overt disease, is therefore a necessary first step
to identifying and correcting microbial configurations that
are implicated in disease.
In this review, we use “healthy” to refer to the absence
of any overt disease (as defined in [10], unless otherwise
specified for particular studies). Most available data de-
scribe the gut microbiome and so many of the findings
discussed here are from this area, though most princi-
ples apply to microbial habitats throughout the body.
Early research into the ecology of the microbiome
sought to identify a “core” set of microbial taxa univer-
sally present in healthy individuals who lack overt dis-
ease phenotypes, under the hypothesis that the absence
of such microbes would indicate dysbiosis [11]; but stud-
ies of ecological diversity among healthy individuals
revealed sufficient variation in the taxonomic compos-
ition of the microbiome to rapidly render such a hypoth-
esis unlikely [11, 12]. Even shared taxa, from individualticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Diversity of recent microbiome research, which has
focused mainly on the gut
Publications
Terms All 2011–2016
Gut | colon | intestinal 17,546 10,707
0ral | mouth | tongue | tooth | subgingival |
supragingival
4843 2089
Urogenital | vaginal | penile 1477 706
Skin | cutaneous 1372 754
Airway | lung 764 524
Placenta | breast milk 702 426
Ocular | eye 152 82
Number of results obtained by searching for “(microbiome | microbiota |
microflora) (<Terms>)” on PubMed (retrieved 31 March 2016)
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by more than an order of magnitude among healthy in-
dividuals [7, 11]. Characterizing a “healthy” microbiome
as an ideal set of specific microbes is therefore no longer
a practical definition [2, 6].
An alternative hypothesis is that of a healthy “func-
tional core”: a complement of metabolic and other mo-
lecular functions that are performed by the microbiome
within a particular habitat but are not necessarily pro-
vided by the same organisms in different people [6].
Such a core might need to be present as genetic potential
(that is, encoded within DNA metagenomes) much as the
human genome must not encode serious deleterious mu-
tations to be healthy or it may need to be expressed and
well-regulated within an individual for him/her to remain
healthy (that is, it must be encoded by RNA metatran-
scriptomes or present in the form of protein or small mol-
ecule products), or of course a combination thereof. The
functional core must, of course, include at least the house-
keeping functions necessary for individual microbial life,
which must be present genomically and correctly
expressed; interestingly, these properties may also include
functions specific to microbes’ niches in the human eco-
system. Such functions may include processes that are not
carried out by human cells and thus represent a potential
basis for symbiotic host–microbial relationships. A healthy
microbiome may be characterized further by its behavior
over time [2, 8]; intuitively, a health-associated micro-
biome must have a degree of resilience to external
(for example, dietary or pharmaceutical) or internal
(for example, age- or stochastic-drift-related) changes.
Even if a particular community structure provided all ne-
cessary core functions, without this resilience it could not
guarantee these functions for long. Thus, the resistance of
a microbiome to stress and perturbation and its ability to
recover to a healthy functional profile afterwards are
among the potential properties that characterize a healthy
microbiome [2, 13].
Here, we review the current characterization of the
healthy microbiome in terms of the normal microbial
residents and their core functions, ecological properties,
and temporal dynamics. We conclude by identifying key
outstanding questions and research directions in this field
and speculate on their solutions and impact. A combin-
ation of recent technological advances and activity within
the field has driven a surge of interest in the human
microbiome in health and disease (Table 1) and thus this
review aims to summarize the variety of current perspec-
tives on what may constitute a healthy microbiome.
Our evolving understanding of the healthy
microbiome
Early studies sought to identify the normal set of mi-
crobes that colonize healthy people, primarily in the gut,by culture and characterization of physiological proper-
ties. Such studies best highlight organisms that grow
well in the lab environment, such as Escherichia coli.
This bias led to the perception that E. coli is an abun-
dant and prevalent member of the human gut micro-
biome [14]. The introduction of strictly anaerobic
techniques in the 1970s allowed the recovery of more
than 300 bacterial species from the gut alone [15];
furthermore, the counting of viable cells within stan-
dardized serial dilutions in selective media permitted
quantification of these species. A summary of four large
studies from this era [12] looking at stool samples from
141 Americans on different diets found that bacteria of
the genus Bacteroides and anaerobic cocci were both
prevalent and abundant, whereas the genus Clostridium
was ubiquitous in lower abundance, though no single
species (as then defined) was observed in all subjects.
Other prevalent but lower-abundance bacteria included
members of the genera Bifidobacterium, Eubacterium,
Lactobacillus, and Streptococcus, as well as facultative
anaerobes such as Escherichia.
It was already suspected at this time that a large num-
ber of human-associated microbial species remained un-
discovered, with one study estimating the simultaneous
presence of some 400 microbial species in a healthy
colon [16, 17]. However, the fastidious requirements of
some microbes and the labor-intensive nature of the
work required to culture them presented a significant
barrier to their discovery [12]. Further, not all microbes
can be well-distinguished as species or strains by cultur-
ing on selective media alone; for example, the different
high-abundance Bacteroides species are particularly diffi-
cult to disentangle [12, 17]. In addition, such studies of
community composition were even more difficult to ex-
tend to non-bacterial microbes, such as viruses and
fungi, and were even more impractical for studies of
body habitats that are less microbially rich than the gut.
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the healthy microbiome.
Culture-independent techniques such as DNA sequen-
cing [18] and fluorescence in situ hybridization (FISH)
[19] are now widespread and their democratization has
allowed the DNA content of microbial samples to be in-
terrogated directly [20]. Early studies using FISH target-
ing the 16S ribosomal RNA gene suggested that at least
two-thirds of the gut bacteria in a western European
cohort could be attributed to a set of six groups at ap-
proximately the species/genus level: two Bacteroides,
two Clostridium, Streptococcus/Lactococcus, and Eubac-
terium rectale [19]. This has since proved to be optimis-
tic and, even at the time, large variability was observed
in the abundances of these groups between samples
(standard deviations of ~60–80 % of their means) [19].
Some of the earliest efforts to sequence 16S rRNA
genes directly from samples showed that 85–95 % of
bacterial abundance corresponding to known species
could be attributed to three bacterial groups related to
Bacteroides, Clostridium cluster XIVa, and Clostridium
cluster IV [21, 22]. 16S studies also showed a large diver-
sity in the taxonomic composition both between healthy
people and among closely linked biogeographical sites
within a single person (such as mucosal and stool sam-
ples [23]). However, in all of these studies, the majority
(75–80 %) of sequence clusters did not match any docu-
mented species at the time [21–23], explaining much of
the underestimation of diversity in previous work.
The advent of massively parallel shotgun sequencing
(high-throughput sequencing technologies) has substan-
tially resolved the taxonomic composition of this micro-
bial “dark matter” [24], although a striking percentage of
functional diversity remains to be characterized (up to
50 % [25]) as does the composition of non-reference
populations (discussed below). Initial findings echoed
the large interpersonal differences, even between twins
[26], but also implied the existence of a set of microbial
genes that are common to all individuals [26, 27]. This
helped seed the model that, like conserved housekeeping
genes in individual organisms, a “core microbiome” can
be defined at the functional rather than at the taxonomic
level [26, 27].
Population-scale baseline cohorts
Large-scale projects have since been launched to
characterize the diversity of microbial composition and
its functional potential, building on the still-increasing
throughput and cost-effectiveness of sequencing and
other molecular assays. In 2010, the Metagenomes of
the Human Intestinal Tract (MetaHIT) study reported
gut metagenomes from stool samples from a cohort of
124 European adults (predominantly ‘healthy’), which at
the time exceeded the sequencing volume of all previousmicrobiome studies by almost 200-fold [9]. In 2012, the
Human Microbiome Project (HMP) reported the results
of 16S profiling on 242 healthy adults from the United
States and metagenomic sequencing on a subset of 139
individuals, with samples representing 18 body habitats
distributed between five major body areas [7]. A large
Chinese study on type 2 diabetes soon contributed an
additional 145 gut metagenomes, approximately half of
which were from non-diabetic controls [28]. Further, the
MetaHIT consortium has since continued to publish
new gut metagenomes from European adults [29–31].
Altogether, the number of population-scale healthy micro-
biomes surveyed in the gut and other body sites now
exceeds 2000 individuals spanning multiple continents.
Typical components and diversity of the
microbiome
Bacterial components of a healthy microbiome
The ecosystem of the colon has been the most inten-
sively studied body habitat (Table 1) as it boasts a re-
markable diversity between people and a microbial
biomass (cell count) that eclipses that of other body sites
by more than an order of magnitude [32]. In combin-
ation with the early rise of 16S rRNA gene sequencing
and anaerobic culture techniques, these properties of the
gut have led to a particularly strong focus in the litera-
ture on bacterial gut microbiome residents. Over 1000
gut bacterial species have now been characterized [15],
providing a significant “parts list” of bacterial constitu-
ents. Interestingly, molecular phylogenetics has led to
the reclassification of many of these species in the past
20 years. Of particular interest, species within Bacter-
oides, previously considered the most prevalent and
abundant bacterial genus in the gut, have been reclassi-
fied into five genera: Alistipes, Prevotella, Paraprevotella,
Parabacteroides, and Odoribacter, with additional culture-
based and culture-independent molecular work ongoing
[15]. An estimated 1000–1150 bacterial species were
prevalent in the MetaHIT cohort’s gut microbiomes,
of which each person carried ~160 species on average
[9]. Healthy gut microbiomes as assessed by sequen-
cing are consistently dominated by bacteria of two
phyla—Bacteroidetes and Firmicutes [7, 9]—though
even when considering this broad level of classifica-
tion, individuals vary by more than an order of mag-
nitude in their Firmicutes/Bacteroidetes ratios [7].
Prevalent bacteria in feces that have been identified
through molecular techniques have broadened the
lists above to include bacteria from at least eight fam-
ilies (Fig. 1a).
Although less well-studied than the gut, many other
body habitats within healthy individuals are occupied
by microbial communities [7]. Community compos-
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Fig. 1 Possible definitions of a healthy microbiome: composition, function, dynamics, and ecology. a Early definitions of a “healthy” microbiome
generally focused on sets of taxa that might be expected to be found prevalently in healthy people. While purely taxonomic cores of any type
have remained elusive, even in relatively narrowly defined populations, each body-site habitat possesses strong phylogenetic enrichments. Typical
genera (or families in the gut) in healthy populations at different sites are shown here [7, 9, 15, 33–35]. b Metagenomic measurements have
allowed the functional potential of the microbiome at different sites to be assessed. These studies have yielded more consistently shared functional
cores of body-wide and niche-specific pathways that are maintained in health [6, 7, 9, 98]. LPS lipopolysaccharide, PAMP pathogen-associated molecular
pattern. c Ecological assembly patterns provide another possible definition of a healthy microbiome, because each host may draw from a “typical”
meta-population of potential microbes through a mix of partially stochastic processes. These processes may include the order in which microbes
colonize their respective human habitat (affected by geography and early exposures, for example), the prolonged availability of each microbe in the
host’s local environment, and host selection (through diet or genetics, adapted from Fig. 1 of [101]). d The healthy microbiome can also
be characterized in terms of its dynamics, depicted here in a simplified model as a conceptual energy landscape. The infant microbiome
(yellow point) starts out in an unstable state and gradually descends towards one of potentially several healthy adult attractor states. Perturbations
(dashed red arrows) can either be resisted (green point) or can move the microbiome out of the healthy state, after which a resilient microbiome will
return to a healthy state (not necessarily the original healthy state) or fall into an unhealthy state (red)
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with oral communities in other people than with other
habitats within the same person), although, in turn, inter-
individual differences within habitats are much greater
than intra-individual variability over time [7]. Oral sites
harbor particularly diverse microbiomes [33], similar in
complexity to the microbiome of the gut [7], and tend to
be dominated by Streptococcus spp. [7]. Skin sites differ
primarily with the local properties of the skin (dry versus
moist versus sebaceous [34]) and are colonized primarilyby Corynebacterium, Propionibacterium, and Staphylo-
coccus [34]. The healthy vagina contains one of the
most remarkably structured microbial ecosystems, with at
least five reproducible community types, or “community
state types”, each dominated by a single species of Lacto-
bacillus (L. crispatus, L. iners, L. jensenii, or L. gasseri) or
by a mixture of other microbes including Gardnerella
[35, 36]. Significant determinants of a woman’s commu-
nity state type include race/ethnicity [35, 37] and preg-
nancy [37], although even in this structured ecosystem
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date, has no fully explained causes.
Several significant body habitats tend to have particu-
larly low microbial biomass in healthy individuals and are
thus more difficult to characterize. The lung, for example,
is near-sterile in the absence of infection or chronic dis-
ease, leading to great interest in identifying its normal res-
idents but also to substantial technical challenges in
sampling and sequencing the site [38–40]. Likewise, breast
milk [41] and the placenta [42] are of interest for the early
establishment of both a healthy microbiome and the
potential circulating blood [43] or tissue [44, 45] micro-
biomes for normal immune control of opportunists. There
are considerable difficulties in acquiring metagenomes
from such environments and thus most studies have relied
on contamination-sensitive amplicon surveys [46] and
relatively low-throughput single-cell techniques, such as
FISH or microfluidics. Larger-scale carefully controlled
studies are thus needed to establish the functionality of
these challenging low-density microbial habitats.
Archaea, viruses, fungi, and other eukaryotes
The study of the healthy microbiome has been greatly
enriched for bacteria [7, 9], with less attention given to
other microbial domains. The human microbiome,
though, spans the tree of life and thus includes archaea,
viruses, and eukaryotes. A small number of archaeal
genera have been identified in the healthy human micro-
biome, primarily in the gut. Species of the Methanobre-
vibacter genus are the most prevalent [47] in the gut,
with their status as “healthy” members of other body
sites’ communities remaining somewhat unclear [48].
Methanobrevibacter smithii in particular has been found
to be well-adapted to the human gut, optimizing the di-
gestion of dietary polysaccharides by other microbes [49]
and adapting its gene expression in the presence of com-
mon gut bacteria such as Bacteroides thetaiotaomicron
[49]. The human virome is particularly extensive and,
while under-characterized, is recognized as an integral
part of the healthy human ecosystem [50]. With the hy-
pervariable nature of viruses, each person is expected to
harbor a unique virome [51, 52], consisting primarily of
bacteriophages [50] (an estimated 5 % of the gut bacter-
ial gene complement codes for prophage proteins [9]).
Phages also provide an additional means of horizontal
gene transfer among otherwise distantly related bacteria
[53]. As molecular-profiling techniques for archaea, vi-
ruses, and eukaryotes are still less well-developed than
those for bacteria (even those using culture-independent
approaches [47, 54]), information on the molecular func-
tionality of these organisms within in situ communities
remains limited.
Although the best-known eukaryotic microorganisms
found in or on the human body (principally fungi andprotists) are typically pathogens, it is important to re-
member that many such eukaryotes, in particular
Candida, Malassezia, and Saccharomyces, are pervasive
even in healthy populations [55–58]. Trans-kingdom in-
teractions are responsible for at least part of the ecological
and immune balance of the healthy microbiome; for ex-
ample, there is apparent competition between bacteria
and fungi across skin biochemical environments [59] or in
Lactobacillus control of fungi in the gut [55] and vagina
[60]. Although few examples exist, direct mutualistic rela-
tionships between humans and fungi have been found, of
which the best-characterized involves the probiotic yeast
Saccharomyces boulardii, originally isolated to combat
cholera [61]. Some protozoa are even common inhabitants
of healthy microbiomes [58, 62], albeit (like viruses) with
even greater interpersonal variability than bacteria [58].
Further, the presence of some protozoa, such as the com-
mon Blastocystis, has been associated with reduced risk of
gastrointestinal disease [63]. Finally, although multicellular
eukaryotes such as helminths have generally been elimi-
nated from gut microbiomes in Western cultures, they
have been a component of the gut microbiome for a sig-
nificant portion of our recent evolutionary history [64].
Given their potent immunomodulatory capabilities and
interactions with the other inhabitants of the normal gut
microbiome (such as Lactobacilli [65]), their elimination
may have removed an important educator of our immune
systems [64].
Geographical variation in the healthy microbiome
Studies contrasting the gut microbiomes from different
countries have identified systematic differences in micro-
bial composition, although it remains challenging to
tease apart inter-batch technical effects from inter-
population biology. Comparison between the largest
cohorts from three continents—MetaHIT (European),
HMP (American), and Chinese diabetes cohorts—found
that the inter-country variation in taxonomic composition
significantly exceeded inter-personal variation, which was
not solely attributable to technical differences in experi-
mental methodologies [29]. Nevertheless, smaller inter-
national studies have also identified geography as one of
the major sources of large-scale variation in the micro-
biome, including between North and South America [66],
Europe and Africa [67], Korea and Japan [68], and between
rural and urban populations of Russia [69] and China [70].
Among possible drivers of this variation, diet has been sug-
gested as an important contributor [67], along with other
factors including geography, early-life exposures, and gen-
etics [29, 71]. No one study has yet shown any of these fac-
tors to be causal in the large observed inter-population
differences in healthy microbiomes [72].
Geographic differences at the strain level are also of
interest, particularly as strain signatures exhibit greater
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[8, 73, 74]. Research in this area is preliminary but shows
that strain differences are not particularly pronounced
between countries or continents. Species such as Bacter-
oides coprocola and Prevotella copri show the greatest
differences [73] and strain-level variants in antibiotic re-
sistance genes spanning populations [75]. Strain-level
microbial forensics on highly heritable species such as
Helicobacter pylori have been remarkably insightful in
tracing historical effects on the microbiome [76, 77] and
culture-independent techniques should be leveraged for
thorough large-scale population surveys in the future.
Microbiome establishment and early colonization
Factors that influence early-life microbiome dynamics
are important precipitators of a healthy microbiome. Mi-
crobial introduction and persistence is a semi-stochastic
process influenced by many elements (Fig. 1c), yielding a
healthy adult-like configuration only after the first few
years of life [66, 78–80]. Enrichment of the infant gut
microbiome for symbionts such as Bacteroides, Parabac-
teroides, Clostridium, Lactobacillus, Bifidobacterium,
and Faecalibacterium prausnitzii provides several deter-
minants of a healthy microbiome. Once established,
these are the main producers of short chain fatty acids
(SCFAs), an important source of energy from non-
digestible carbohydrates [81]. SCFAs are immunomodu-
latory [82], inhibit common pathogens, and are hypothe-
sized to possess tumor-suppressive properties [83, 84].
The gut microbiome is an inextricable requirement for
immune system education and the establishment of
these beneficial genera early in life promotes immune
tolerance and can consequently attenuate or abrogate
autoimmune diseases [1, 85–89].
Delivery mode can affect early-life establishment of
microbiota such that Caesarean section is associated
with enrichment for opportunists, including Haemophi-
lus spp., Enterobacter cancerogenus/E. hormaechei, Veil-
lonella dispar/V. parvula [78], and Staphylococcus [80].
These microbes continue to persist at least throughout
the first year of life [78] and possibly contribute to infant
infection burden. Diet also represents a strong selective
pressure on the microbiome [71, 90] and breast-feeding
(as the first diet) favors certain microbial clades from
among the initial microbiota that may have assembled at
random. For example, human milk oligosaccharides
(HMO) can be used as the sole carbon source by only a
handful of Bifidobacterium and Bacteroides species [91]
and, more so, bovine milk oligosaccharides (BMO) were
recently shown to promote growth and metabolism in a
microbiota-dependent manner in animal infant models
[92]. While this model may not translate directly to hu-
man infants because of the unique structural diversity,
complexity, and high concentration of HMO [93, 94], itlends further support to the inference that the long-term




While large interpersonal differences are observed in
the taxonomic composition of the microbiome at all
sites, the abundance of metabolic pathways is consid-
erably more consistent across people for a given site
[7, 9, 26, 27]. Further, while the composition of the
microbiome changes drastically over the first years of
life, this functional profile is established early on and
remains stable thereafter, at least in the gut [72]. This
suggests that one definition of a “core” healthy micro-
biome might include specific microbial gene family
combinations, metabolic modules, and regulatory path-
ways that together promote a stable host-associated ecol-
ogy [96, 97]. This core includes functions from at least
three groups: first, and most simply, the housekeeping
functions necessary for all microbial life, such as transcrip-
tion and translation, energy production, and structural
components [6, 7, 9]. Second, this core includes processes
that are specific to human-associated microbiomes across
body-site habitats, such as adhesion to host cell sur-
faces and the production of compounds implicated in
host–microbe interaction (including essential vitamins,
such as vitamin K, and immunostimulatory compounds)
[6, 7]. Finally, different body habitats each have their own
specialized core functions [98]. For example, in the gut,
core functions include glycosaminoglycan biodegradation,
the production of several short-chain fatty acids, enrich-
ment for specific lipopolysaccharides, and the production
of vitamins and essential amino acids [6, 9, 98, 99]
(Fig. 1b). Which of these functions tend to be enriched in
a given population can be affected by long-term selective
pressures such as diet [67]. A necessary condition for a
healthy microbiome is therefore the presence of an assem-
blage of microbial species that can carry out specific sets
of biomolecular functions in each of the niche-specific
biochemical environments across the body.
Healthy community ecology
If microbial communities assemble on the basis of their
coverage of a core set of functions while selecting from a
large meta-population of potential colonizers, they are
likely to be ecologically diverse [100–102], both in terms
of richness (number of taxa present) and evenness
(abundance of many microbial constituents). High diver-
sity has been generally associated with health [11] and
temporal stability [103]. The latter could, for example,
be the result of the increased functional redundancy that
comes with a more diverse set of microbes, even if
the functional potential of the assembly is minimally
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of diversity is apparent in the gut microbiome in dis-
eases ranging from obesity [26] to inflammatory
bowel disease [104] and types 1 [72] and 2 [28] dia-
betes; and in the skin microbiome in atopic dermatitis
[105] and psoriasis [106]. Antibiotics also cause a
drastic reduction in the diversity of the microbiome
with highly variable recovery dynamics [107], poten-
tially weakening the community’s ability to exclude
pathogens. This may clear the way for infection by
pathobionts—normal microbial community members
that become detrimental under perturbation, such as
Candida albicans [57]. The principle that high diversity is
“healthy” does not hold for all body sites, however, as
diversity in the vaginal microbiome can be associated with
bacterial vaginosis [108], cervical intraepithelial neoplasia
[109] (an abnormal growth on the cervix), pre-term birth
[36], and inflammation [110].
Given the typical observation of increased microbiome
diversity in health, it has been hypothesized [111] that
developed countries’ consistently reduced gut microbial
diversities may account for higher chronic disease rates
relative to those seen in developing countries and primi-
tive societies [66, 112, 113], termed the “disappearing
microbiome hypothesis” [111]. This loss of diversity may
be linked to a high-fat, high-refined-sugar, and low-fiber
diet [114]. Humanized mice on such a diet exhibit a
depletion in microbial diversity [114] and though this is
recoverable by returning to a high-fiber diet within a
generation, it becomes fixed after four generations [114].
If this result generalizes to human populations, it in-
creases the urgency of developing rationally targeted
microbiome maintenance or therapeutic methods, so as
to steer less health-promoting microbiomes towards
more natural assemblages. The disappearing microbiome
hypothesis in some ways represents an evolution of the
“hygiene” or “old friends” hypotheses [115], all of which
suggest that while modern North American or European
cohorts may represent “healthy” microbiomes, their rela-
tionship to what is evolutionarily “normal” may be more
complex.
Resistance, resilience, and stability
Other hallmarks of health from the microbial ecology
perspective are the ability to resist perturbation (which
might result from the entry of a pathogen, alteration of
diet, or medication) and to return to a healthy state
afterwards. These properties have been termed resist-
ance and resilience, respectively [2]. For example, after
an antibiotic treatment, healthy gut communities gener-
ally recover to their previous state after a few weeks to
months [116]. A recent definition of microbial health
thus explicitly comprises not a single static state but ra-
ther a dynamic equilibrium [2]. In this view, a healthymicrobiome corresponds to an attractor of an underlying
dynamic system (Fig. 1d), in a similar manner to cell fate
in a metazoan [117]. Attractors capture both resistance
and resilience, in that the system will resist a departure
from an attractor, and unless a fluctuation (which might
be due to external perturbation or internal stochasticity)
is sufficiently large, it will tend to return to the steady
state area [117]. The most visible examples in the human
microbiome may be transitions between community
state types in the healthy vagina; although their specific
health implications are not yet enumerated, not all com-
munity state types have the same degree of stability [36].
The gut microbiome is also in flux, gaining and losing
species over time, with different taxa having different
stabilities and with some consistently remaining in the
gut for many years [8]. The mechanisms by which spe-
cific taxa persist are not yet well-delineated, but it is in-
teresting to speculate whether such mechanisms might
relate to the driving principles behind the assembly of
the microbiome. If specific communities do assemble
primarily to fill a suite of habitat-suited functional niches
[6], then species that provide key metabolic, signaling,
immunomodulatory, or other roles in a particular as-
sembly may be more temporally stable than those in the
functional periphery. Coupling dynamics with the taxo-
nomic diversity and immense molecular functional po-
tential of the microbiome is thus a reminder of the
human microbiome’s complexity and, as a result, the dif-
ficulty of defining even the apparently simple concept of
microbial health.
Outlook
The era of population-scale whole-microbiome epidemi-
ology has only recently begun, with the HMP [7, 118]
and MetaHIT [9, 29] among the first large cohorts to in-
clude broad reference data in health, and several more
cohorts soon to come. Data to date have been domi-
nated by cross-sectional, amplicon-based studies of
Western populations, all of which are efficient and
accessible but which do not yet paint a consistent, com-
prehensive picture of the global, dynamic, healthy micro-
biome. Large-scale epidemiology in other areas of
human health, such as nutrition and lifestyle, has built a
solid foundation for prospective, long-running cohorts,
painstaking analyses, and carefully validated measure-
ment instruments [119–121], all of which represent
particularly promising avenues of exploration for the
microbiome. Nesting longitudinal microbiome studies in
existing cohorts has the advantage of utilizing long-term
collected lifestyle, dietary, medical, and phenotype infor-
mation, as well as integration with banked biospecimens.
An example of an unconventional large-scale study, not-
able for its infrastructure and outreach, is the American
Gut project: a crowd-funded source of microbiome
Lloyd-Price et al. Genome Medicine  (2016) 8:51 Page 8 of 11reference data paired with subject-provided environmen-
tal metadata. Prospective studies with detailed molecular
data, while more expensive and logistically challenging,
will also be necessary to facilitate predictive models and
to establish the causality of dysbioses. The ongoing
“HMP2” or Integrative Human Microbiome Project
(iHMP) [122] includes three such longitudinal studies,
which are providing multi-omic data for health and
chronic disease, along with protocols and computational
tools as a foundation for future work.
While many current studies of the microbiome focus
on disease, a better understanding of the healthy micro-
biome will itself help to develop new microbial commu-
nity diagnostics and therapeutics [123]. To the degree
that universal features of the healthy microbiome can be
defined, their absence may be predictive of disease onset
generally, much like the presence of features specific to
any one condition’s dysbiosis (especially useful if it oc-
curs prior to disease onset). Alternatively, personalized
medicine and longitudinal monitoring may serve the
same purpose with respect to departure from an individ-
ual’s own “healthy” state [1, 104]. Therapeutically, as tar-
geted interventions are developed to manipulate the
microbiome, the treatment of a dysbiosis need not re-
turn to the healthy state from which an individual
departed (due to a perturbation such as antibiotic treat-
ment or the invasion of a pathogen), but perhaps only to
a healthy state (Fig. 1d). Likewise, even if a microbial
dysbiosis proves to be responsive rather than causal in
any given disease state, the return to a “healthy” state
may still provide therapeutic benefit [73, 101, 124].
One of the biggest outstanding gaps in understanding
the basic biology of the “healthy” microbiome is per-
haps at the level of annotating its molecular function:
up to 50 % of microbial gene families encountered in
the human microbiome remain functionally uncharac-
terized, even in well-studied environments such as
the gut [9, 25, 29]. This is to a degree true in individ-
ual microbial isolate genomes as well, where even the
well-studied E. coli K12 contains some 18 % of gene
products with no reported function [125], with appre-
ciably more at the E. coli species pangenome level [126]. It
is likely, for example, that some of these genes are respon-
sible for microbe–microbe or host–microbe interactions
and thus will only be expressed or characterizable in com-
munity settings. Population-scale studies of the micro-
biome can themselves be used to mitigate this situation
partially, in that microbial gene families that are prevalent
and abundant but not yet well-understood can be priori-
tized for characterization. Likewise microbial communities
provide a new source of guilt-by-association information
that can be used computationally to generate predictions
of gene function [127, 128]. Nevertheless, returning to the
field’s microbiological roots may ultimately prove mostimportant in this area: the best biochemical characteriza-
tions still derive from culture-based physiology, microbial
metabolism, co-culture and interactions, and controlled
laboratory environments coupled with high-throughput
molecular assays [15, 129, 130].
Studies of the microbiome, both in health and in dis-
ease, must continue to integrate population-scale epi-
demiology with narrow but deep clinical studies in the
setting of personalized medicine. In both cases, studies
of the body-wide microbiome can be seen as an exten-
sion of microbial techniques already used for infectious
disease surveillance [131]: rather than waiting to moni-
tor a pathogen’s outbreak in a population or its persist-
ence within an individual, our complete microbial
community could be monitored for health maintenance
or departures into disease. This is equally true in the in-
tegration of microbiome activity with host immune,
transcriptional, epigenetic, and clinical state: precision
microbial community medicine must rely on host–
microbiome interactions as a key component. This will
help to identify potential pathogens rapidly [132] and
will make it possible to determine the “right” interven-
tions to restore health after dysbiosis, ranging from
dietary or lifestyle changes through probiotics into
microbially targeted pharmaceuticals [133]. A better
understanding of the healthy microbiome must thus ap-
proach it as one aspect of deeply monitored personalized
health (e.g., [121]) and must integrate population-scale
assessment of the microbial community with a well-
characterized molecular understanding and analyses of
how beneficial community states are maintained body-
wide and life-long.
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